Benchmark Upgrades AbCellera Biologics (ABCL) to Buy, 'R&D Progress Highlights 4Q23'
Tweet Send to a Friend
(Updated - February 22, 2024 9:40 AM EST)
Benchmark analyst Robert Wasserman upgraded AbCellera Biologics (NASDAQ: ABCL) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Benchmark analyst Robert Wasserman upgraded AbCellera Biologics (NASDAQ: ABCL) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
